MA49830A - Traitement à l'obinutuzumab d'un sous-groupe de patients dlbcl - Google Patents

Traitement à l'obinutuzumab d'un sous-groupe de patients dlbcl

Info

Publication number
MA49830A
MA49830A MA049830A MA49830A MA49830A MA 49830 A MA49830 A MA 49830A MA 049830 A MA049830 A MA 049830A MA 49830 A MA49830 A MA 49830A MA 49830 A MA49830 A MA 49830A
Authority
MA
Morocco
Prior art keywords
patient subgroup
dlbcl patient
obinutuzumab
treatment
obinutuzumab treatment
Prior art date
Application number
MA049830A
Other languages
English (en)
French (fr)
Inventor
Mikkel Zahle Oestergaard
Original Assignee
Hoffmann La Roche
Nanostring Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Nanostring Technologies Inc filed Critical Hoffmann La Roche
Publication of MA49830A publication Critical patent/MA49830A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA049830A 2017-08-08 2018-08-08 Traitement à l'obinutuzumab d'un sous-groupe de patients dlbcl MA49830A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762542489P 2017-08-08 2017-08-08

Publications (1)

Publication Number Publication Date
MA49830A true MA49830A (fr) 2021-03-31

Family

ID=63209389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049830A MA49830A (fr) 2017-08-08 2018-08-08 Traitement à l'obinutuzumab d'un sous-groupe de patients dlbcl

Country Status (20)

Country Link
US (2) US11597772B2 (OSRAM)
EP (1) EP3665196B1 (OSRAM)
JP (2) JP7418322B2 (OSRAM)
KR (1) KR102799421B1 (OSRAM)
CN (2) CN111032692A (OSRAM)
AU (1) AU2018314765C1 (OSRAM)
CA (1) CA3071618A1 (OSRAM)
CR (1) CR20200061A (OSRAM)
ES (1) ES2933256T3 (OSRAM)
IL (1) IL272418B2 (OSRAM)
MA (1) MA49830A (OSRAM)
MX (1) MX2020001493A (OSRAM)
MY (1) MY202382A (OSRAM)
PE (1) PE20200738A1 (OSRAM)
PL (1) PL3665196T3 (OSRAM)
SG (1) SG11202000985XA (OSRAM)
TW (1) TWI772488B (OSRAM)
UA (1) UA126204C2 (OSRAM)
WO (1) WO2019030260A1 (OSRAM)
ZA (1) ZA202000680B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング,インコーポレイテッド Tim-3とそのリガンドとの相互作用の遮断によるがん治療
EP3665196B1 (en) * 2017-08-08 2022-10-19 F. Hoffmann-La Roche AG Obinutuzumab treatment of a dlbcl patient subgroup
EP3873942A4 (en) * 2018-10-29 2022-12-28 Tigatx, Inc. Compositions and methods comprising iga antibody constructs
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0238090B1 (en) 1986-03-20 1997-02-05 Nec Corporation Microcomputer capable of accessing internal memory at a desired variable access time
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたFcレセプター結合親和性及びエフェクター機能をもつCD20抗体
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US20130195843A1 (en) * 2010-06-23 2013-08-01 British Columbia Cancer Agency Branch Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
DE102013222576A1 (de) 2013-11-06 2015-05-07 BSH Bosch und Siemens Hausgeräte GmbH Haushaltsgerät
US10607717B2 (en) * 2013-11-06 2020-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for subtyping lymphoma types by means of expression profiling
PL3066126T3 (pl) 2013-11-07 2019-08-30 F. Hoffmann-La Roche Ag Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK
EP3122900A1 (en) * 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3193932B1 (en) * 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
SI3262071T1 (sl) * 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Način uporabe imunokonjugatov proti CD79b
MX392539B (es) * 2015-06-08 2025-03-24 Debiopharm Int Sa Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20.
MX2017016651A (es) 2015-06-24 2018-05-14 Hoffmann La Roche Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias.
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
EP3178848A1 (en) * 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP3665196B1 (en) * 2017-08-08 2022-10-19 F. Hoffmann-La Roche AG Obinutuzumab treatment of a dlbcl patient subgroup

Also Published As

Publication number Publication date
WO2019030260A1 (en) 2019-02-14
KR102799421B1 (ko) 2025-04-30
JP2023179425A (ja) 2023-12-19
NZ761111A (en) 2024-05-31
AU2018314765A1 (en) 2020-01-30
IL272418B1 (en) 2024-05-01
JP7418322B2 (ja) 2024-01-19
CR20200061A (es) 2020-05-23
PE20200738A1 (es) 2020-07-23
SG11202000985XA (en) 2020-02-27
US20230348611A1 (en) 2023-11-02
KR20200035441A (ko) 2020-04-03
MY202382A (en) 2024-04-24
JP2020530002A (ja) 2020-10-15
IL272418A (en) 2020-03-31
CN111032692A (zh) 2020-04-17
AU2018314765B2 (en) 2025-03-20
AU2018314765C1 (en) 2025-11-20
CA3071618A1 (en) 2019-02-14
TWI772488B (zh) 2022-08-01
CN119798437A (zh) 2025-04-11
EP3665196A1 (en) 2020-06-17
ES2933256T3 (es) 2023-02-03
TW202323297A (zh) 2023-06-16
MX2020001493A (es) 2020-03-24
PL3665196T3 (pl) 2023-01-23
UA126204C2 (uk) 2022-08-31
TW201910353A (zh) 2019-03-16
IL272418B2 (en) 2024-09-01
US20200317800A1 (en) 2020-10-08
US11597772B2 (en) 2023-03-07
ZA202000680B (en) 2024-09-25
EP3665196B1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
EP3600130C0 (en) Generating a virtual depiction of an orthodontic treatment of a patient
MA49830A (fr) Traitement à l'obinutuzumab d'un sous-groupe de patients dlbcl
EP3813634A4 (en) ARTICULATING MEDICAL INSTRUMENTS
EP3814567A4 (en) LAUNDRY CARE DEVICE
EP3515505A4 (en) AAV TREATMENT BY MORBUS ALZHEIMER
IL271046A (en) Compounds for treating huntington's disease
EP3691549A4 (en) BLOOD STOPPER OR RESTRICTION CUFF
EP3817747A4 (en) TARGETED DELIVERY OF THERAPEUTIC AGENTS TO HUMAN ADIPOCYTES
ITUA20163045A1 (it) Dispositivo spaziatore per il trattamento di un'articolazione del corpo umano
MA53553A (fr) Traitement post-chirurgical de la douleur
EP4072456A4 (en) TISSUE MAPPING AND TREATMENT
PT3773558T (pt) Tratamento combinado de doença artrítica
EP3773632A4 (en) Methods of treating egfrviii expressing glioblastomas
JP1671730S (ja) 医療用加湿器用タブ用部品
EP3850534A4 (en) RECONSTRUCTION OF FINGERPRINT SUB-IMAGES
EP3824131A4 (en) LAUNDRY CARE DEVICE
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
EP4021858A4 (en) TREATMENT OF AZOLES
PL3634428T3 (pl) Lek do zapobiegania lub leczenia infekcji rinowirusowej
LT3749308T (lt) Klasikine fabri liga sergančių pacientų gydymas migalastatu
EP3546449A4 (en) PIPERIDINE-2,6-DIKETONE DERIVATIVE AND TREATMENT OF MORBUS CROHN
EP3735934A4 (en) MEDICAL OBSERVATION INSTRUMENT
EP3898960A4 (en) VARIANTS OF HUMAN ALPHA GALACTOSIDASE
MA53636A (fr) Agent de traitement de troubles dermatologiques
IL286818A (en) Mirikizumab for use in a method of treating crohns disease